La vendita allo scoperto per Phreesia dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Phreesia. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Phreesia (NYSE:PHR) Azioni, Report sulle vendite allo scoperto

Phreesia

Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.

Phreesia Inc

PHARMARON BEIJING U/ADR by PHARMARON BEIJING CO LTD.

PHARMATHER HLDGS LTD by PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd

Pharmagen Inc

PHarol SGPS SA

<p>Phreesia, a leader in patient intake, outreach and activation, and a member of Oracle PartnerNetwork (OPN), today announced that it has achieved Oracle Validated Integration with Oracle Health Electronic Health Record (EHR) Expertise for its integration of the Phreesia platform. Phreesia gives clients a suite of tools to manage patient intake across care settings and service lines. Its logic-driven tools enable healthcare organizations to operate more efficiently and provide a high-quality patient experience at scale.</p>
<p>Expertise is a core tenet of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.oracle.com%2Fpartnernetwork%2Fprogram%2F&amp;esheet=54141464&amp;newsitemid=20241028397645&amp;lan=en-US&amp;anchor=Oracle+PartnerNetwork+%28OPN%29+program&amp;index=1&amp;md5=9c9027d214ba54408668ad3c499afc7f">Oracle PartnerNetwork (OPN) program</a> and allows Oracle partners to highlight their capabilities in a focused area. Ultimately, Expertise is designed to make it easy for customers to identify partners who can deliver quality solutions and minimize risk for their specific needs.</p>
<p>In order to achieve the Oracle Validated Integration with Oracle Health EHR Expertise, partners like Phreesia meet a series of qualifiers, including demonstrating that the integration performs as documented. Learn more about Expertise, including viewing the complete Expertise Catalog, at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.oracle.com%2Fpartnernetwork%2Fexpertise&amp;esheet=54141464&amp;newsitemid=20241028397645&amp;lan=en-US&amp;anchor=www.oracle.com%2Fpartnernetwork%2Fexpertise&amp;index=2&amp;md5=a26a999e7488a420550a8e0477a460aa">www.oracle.com/partnernetwork/expertise</a>.</p>
<p>Customers that use the Oracle Health EHR can enhance patient experience, drive efficiency and improve healthcare outcomes through Phreesia's suite of solutions, including appointment scheduling, patient registration, revenue cycle management and more. Phreesia's research shows that Oracle customers who use Phreesia see a positive impact at their organizations, including increasing payment collections by 25% and collecting 77% of copays at time of service. Additionally, with 87% of patients checking themselves in for an appointment, staff are saving more than five minutes each visit.</p>


News

ORCL

Phreesia Integrates with Oracle Health EHR, Enhances Patient Experience and Efficiency in Healthcare

Contracts

Phreesia Says Its Contract With The CMS Innovation Center For Use Of The Patient Activation Measure Has Been Renewed Through 2029

<p>Providing a diverse range of perspectives from bullish to bearish, 12 analysts have published ratings on Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) in the last three months.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $29.0, a high estimate of $34.00, and a low estimate of $23.00. Marking an increase of 1.15%, the current average surpasses the previous average price target of $28.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1727456492_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Phreesia's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$31.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Joseph Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$34.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Sean Dodge</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$23.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Robert Simmons</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Phreesia compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Phreesia's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Phreesia's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Phreesia analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Phreesia's Background</h2>
<p>Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.</p>
<h3>A Deep Dive into Phreesia's Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Phreesia showcased positive performance, achieving a revenue growth rate of <strong>18.97%</strong> as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Phreesia's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-17.64%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-7.15%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Phreesia's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-4.91%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.07</strong>, Phreesia adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

The Latest Analyst Ratings For Phreesia

<p>RBC Capital  analyst Sean Dodge   reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Sector Perform and maintains $23 price target.</p>


Price Target

Reiteration

RBC Capital Reiterates Sector Perform on Phreesia, Maintains $23 Price Target

<p>JP Morgan  analyst Anne Samuel   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and raises the price target from $27 to $28.</p>


JP Morgan Maintains Overweight on Phreesia, Raises Price Target to $28

<p>Truist Securities  analyst Jailendra Singh   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and raises the price target from $29 to $31.</p>


Truist Securities Maintains Buy on Phreesia, Raises Price Target to $31

<p>Baird  analyst Joseph Vruwink   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Outperform and raises the price target from $31 to $34.</p>


Baird Maintains Outperform on Phreesia, Raises Price Target to $34

<p>JMP Securities  analyst Joe Goodwin   reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Market Outperform and maintains $30 price target.</p>


JMP Securities Reiterates Market Outperform on Phreesia, Maintains $30 Price Target

<p>Canaccord Genuity  analyst Richard Close   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $34 price target.</p>


Canaccord Genuity Maintains Buy on Phreesia, Maintains $34 Price Target

<p>DA Davidson  analyst Robert Simmons   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $32 price target.</p>


DA Davidson Maintains Buy on Phreesia, Maintains $32 Price Target

<p>Needham  analyst Ryan MacDonald   reiterates Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $29 price target.</p>


Needham Reiterates Buy on Phreesia, Maintains $29 Price Target

Earnings

Guidance

Phreesia Sees FY 2025 Revenue $416M - $426M Vs $420.41M Est.; Sees FY 2025 Adj. EBITDA $26M - $31M

<p>Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.35) by 11.43 percent.  The company reported quarterly sales of $102.10 million which beat the analyst consensus estimate of $101.70 million by 0.39 percent.  This is a 18.96 percent increase over sales of $85.83 million the same period last year.</p>


Earnings Beats

Phreesia Q2 2025 GAAP EPS $(0.31) Beats $(0.35) Estimate, Sales $102.10M Beat $101.70M Estimate

<p>Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $28.25, a high estimate of $30.00, and a low estimate of $25.00. This current average has decreased by 6.61% from the previous average price target of $30.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725037234_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Phreesia by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Phreesia compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Phreesia analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Phreesia</h2>
<p>Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.</p>
<h3>Phreesia's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Phreesia's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>20.72%</strong> as of 30 April, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Phreesia's net margin is impressive, surpassing industry averages. With a net margin of <strong>-19.48%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Phreesia's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-7.82%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Phreesia's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-5.31%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Phreesia's debt-to-equity ratio is below the industry average at <strong>0.07</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Phreesia Through 4 Analysts

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.</p>
<ul>
<li>Morgan Stanley cut the price target for <strong>Microchip Technology Incorporated</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities lifted the price target for <strong>Astrana Health, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health shares fell 0.4% to close at $38.20 on Wednesday. <a href="https://www.benzinga.com/quote/ASTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted the price target for <strong>Costco Wholesale Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $850 to $975. Baird analyst Peter Benedict maintained an Outperform rating. Costco shares fell 0.3% to close at $884.31 on Wednesday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush increased <strong>CAVA Group, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) price target from $90 to $100. Wedbush analyst Nick Setyan maintained an Outperform rating. CAVA shares fell 5.5% to close at $85.30 on Wednesday. <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim boosted the price target for <strong>Dutch Bros Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from $30 to $36. Guggenheim analyst Gregory Francfort maintained a Neutral rating. Dutch Bros shares fell 4.3% to close at $39.46 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc cut <strong>Phreesia, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) price target from $27 to $25. Keybanc analyst Scott Schoenhaus maintained an Overweight. Phreesia shares fell 7% to close at $18.82 on Wednesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased <strong>Kimberly-Clark Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) price target from $167 to $174. Piper Sandler analyst Korinne Wolfmeyer maintained an Overweight rating. Kimberly-Clark shares gained 1% to close at $140.79 on Wednesday. <a href="https://www.benzinga.com/quotBe/KM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised <strong>Lantheus Holdings, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) price target from $106 to $127. Leerink Partners maintained an Outperform rating. Lantheus shares jumped 36.7% to close at $106.18 on Wednesday. <a href="https://www.benzinga.com/quote/LNTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Sprouts <strong>TaskUs, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) price target from $14 to $16. Baird analyst David Koning maintained an Outperform rating. TaskUs shares gained 3.1% to close at $14.54 on Wednesday. <a href="https://www.benzinga.com/quote/TASK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised <strong>Annovis Bio, Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) price target from $23 to $30. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Annovis Bio shares fell 17.1% to close at $12.08 on Wednesday. <a href="https://www.benzinga.com/quote/ANVS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p><strong>Check This Out: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39726449/top-4-real-estate-stocks-that-could-lead-to-your-biggest-gains-in-q3">Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3</a></strong></li>
</ul>


Markets

Trading Ideas

ANVS

ASTH

BROS

CAVA

COST

LNTH

MCHP

TASK

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

<p>Keybanc  analyst Scott Schoenhaus   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Overweight and lowers the price target from $27 to $25.</p>


Keybanc Maintains Overweight on Phreesia, Lowers Price Target to $25

<p>Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1719856823_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Phreesia. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Joe Goodwin</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$29.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Phreesia. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Phreesia compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Phreesia's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Phreesia's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PHR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Phreesia analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Phreesia</h2>
<p>Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.</p>
<h3>Understanding the Numbers: Phreesia's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Phreesia displayed positive results in 3 months. As of 30 April, 2024, the company achieved a solid revenue growth rate of approximately <strong>20.72%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-19.48%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Phreesia's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-7.82%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Phreesia's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-5.31%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Phreesia's debt-to-equity ratio is below the industry average. With a ratio of <b>0.07</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Phreesia Through 6 Analysts

<p>Truist Securities  analyst Jailendra Singh   maintains Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) with a Buy and maintains $29 price target.</p>


Truist Securities Maintains Buy on Phreesia, Maintains $29 Price Target

In a report released yesterday, Sean Dodge from RBC Capital maintained a Hold rating on Phreesia (PHR – Research Report), with a price target of $2...

RBC Capital Remains a Hold on Phreesia (PHR)

Needham analyst Ryan MacDonald reiterated a Buy rating on Phreesia (PHR – Research Report) today and set a price target of $29.00. Ryan MacDonald's...

Phreesia's Positive Financial Outlook and Attractive Valuation: A Buy Recommendation

In a report released today, Will Jellison from D.A. Davidson maintained a Buy rating on Phreesia (PHR – Research Report). The company's shares clos...

Phreesia (PHR) Receives a Buy from D.A. Davidson

Phreesia: Remain Bullish Given The Healthy Growth Outlook

Phreesia ($PHR) is at the focal point towards the transition to improved healthcare outcomes via patient-driven digital solutions, having partnered...

Phreesia (PHR) Improves Healthcare Outcomes and Expects Growing Clientele

Barclays analyst Stephanie Davis assigned a Buy rating to Phreesia (PHR – Research Report) today and set a price target of $29.00. The company's sh...

Phreesia (PHR) Gets a Buy from Barclays

RBC Capital analyst Sean Dodge maintained a Hold rating on Phreesia (PHR – Research Report) today and set a price target of $23.00. The company's s...

Phreesia rises after new contract

In a report released today, Stephanie Davis from Barclays maintained a Buy rating on Phreesia (PHR – Research Report), with a price target of $29.0...

Comments

Phreesia

Vendite allo scoperto

Phreesia (NYSE:PHR) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO